Not yet recruitingPhase 2NCT06855225

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Studying Carcinoma of liver and intrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mehmet Akce
Principal Investigator
Mehmet Akce, MD
University of Alabama at Birmingham
Intervention
Tremelimumab(drug)
Enrollment
29 enrolled
Eligibility
18 years · All sexes
Timeline
20262027

Study locations (1)

Collaborators

University of Alabama at Birmingham · AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06855225 on ClinicalTrials.gov

Other trials for Carcinoma of liver and intrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Carcinoma of liver and intrahepatic biliary tract

← Back to all trials